Micro Developing Active

LLY's retatrutide mostra resultados mistos do ensaio

Pontuação
0,4
Velocidade
▲ 1,0
Artigos
6
Fontes
2

Resumo

Um artigo pertence a esta narrativa se discutir os resultados mistos do ensaio clínico da retatrutida da Eli Lilly and Company (LLY) para tratamento de diabetes tipo 2.

Artigos Relacionados

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster”

Yahoo Finance · Abr 05, 2026
Mixed

Should You Buy Eli Lilly Stock Before April 10?

Nasdaq · Mar 22, 2026
Mixed

Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial

Yahoo Finance · Mar 22, 2026
Bearish

RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results

Yahoo Finance · Mar 21, 2026
Mixed

Fontes

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be … Yahoo Finance
1 Reason Eli Lilly Stock Is Still a Buy Nasdaq
Should You Buy Eli Lilly Stock Before April 10? Nasdaq
Eli Lilly and Company (LLY) Announces Positive Topline Results From … Yahoo Finance
RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth … Yahoo Finance

Cronologia

Última atualização Mar 21, 2026